This Pre-Solicitation opportunity was posted on April 9, 2018. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

ACAM 2000 Diluent for ACAM 2000 Smallpox Vaccine

Closed

2018-N-67798Federal

Submission Closed05/01/2018, 01:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325414

New

Federal

Custom Homing Peptide Synthesis and AAV Capsid ModificationThis subcontract for the Department of Veterans Affairs, specifically supporting the Harry S Truman Memorial Veterans Hospital, involves the synthesis of targeting peptides and genetic engineering services. The scope of work includes designing homing peptides, modifying AAV capsid genomes for peptide display, and producing modified viral vector prototypes. These activities are to be conducted using molecular cloning tools and DNA/RNA synthesis platforms within BSL-2 facilities. The selected provider must hold BSL-2 certification to deliver the required modified AAV vector constructs and synthesized peptide sequences. Performance of the contract will take place in Columbia, Missouri, under NAICS code 325414. The solicitation was posted on October 21, 2026, with a response deadline of November 4, 2026.

POSTED

DEADLINE

Brand Name - Dectomax (Doramectin) 500mL Injectable Solution

Solicitation # 12639527Q0009

Solicitation 12639527Q0009 is a combined synopsis and request for quotation issued by the Department of Agriculture for the procurement of 2,400 bottles of Dectomax (Doramectin) 500mL Injectable Solution. This firm-fixed-price acquisition is a total small business set-aside under NAICS code 325414 and is intended to support the USDA Cattle Fever Tick Eradication Program in Texas. The required items must be new and the exact brand name specified from Zoetis Inc., as alternate or substitute products are deemed technically unacceptable. All deliverables must be shipped F.O.B. destination to Laredo, Texas, within 30 days of the contract award. Award will be made based on best value, specifically to the lowest priced, technically acceptable offer with an acceptable or neutral past performance rating. To be considered technically acceptable, offerors must provide sufficient documentation, such as manufacturer quotes or datasheets, to verify the product and ensure a clear, auditable paper trail of traceability back to the original equipment manufacturer. Additionally, contractors must furnish a Certificate of Conformance per FAR 52.246-15. Quotations must remain firm for 90 calendar days, and the deadline for submission is October 30, 2026.

POSTED

DEADLINE

Supplier of Pressure Sensitive Adhesive Tape (NSN 7510-01-358-8770)This subcontract involves the supply of Type I Code M pressure sensitive adhesive tape to prime contractors supporting Department of Defense DLA supply contracts. The material must strictly adhere to NSN 7510-01-358-8770 and RA001 technical specifications. The scope of work requires the delivery of eight rolls of mercury-free tape, each maintaining a minimum shelf life of 24 months. Compliance with federal standards is mandatory, including packaging per MIL-STD-2073-1E, marking per MIL-STD-129, and hazardous material labeling according to the Hazard Communication Standard. Deliveries are to be made FOB Origin to DLA Distribution San Joaquin in Tracy, California. The opportunity is categorized under NAICS code 325414.

CONSTRUCTION & EQUIPMENT T & IFO EQ

POSTED

DEADLINE

Supply of Defibrinated Rabbit BloodThis subcontract involves the supply of defibrinated rabbit blood to prime contractors supporting projects for the Defense Health Agency within the Department of Defense. The scope of work includes the collection of rabbit blood, the defibrination process to meet specific requirements, and the bottling of the product into 50ml units. To ensure quality and traceability, the provider must generate lot numbers and product data sheets for every unit produced. The execution of this contract requires the use of biological processing equipment and laboratory-grade bottling facilities. The total deliverable consists of 48 units of defibrinated rabbit blood per period of performance, with the place of performance located in Silver Spring, Maryland. This opportunity falls under NAICS code 325414 and is associated with a response deadline of October 23, 2026.

Defense Health Agency (dha)

POSTED

DEADLINE

PANDHA-26-P-0000 046638 Defibrinated Rabbit Blood

Solicitation # PANDHA-26-P-0000_046638

The Defense Health Agency Contracting Activity, acting on behalf of the Walter Reed Army Institute of Research, intends to award a sole source contract to Lampire Biological Labs, Inc. under FAR 6.302 for the procurement of defibrinated rabbit blood. The requirement is categorized under NAICS code 325414 for Biological Product Manufacturing. The contract structure consists of a base year followed by four one-year option periods, with a delivery requirement of 48 units per period of performance, where each unit is defined as one 50ml bottle. The contractor must ensure each unit is provided with a lot number and an associated product data sheet. Strict packaging and shipping standards are required to prevent leaks, spillage, and damage, while maintaining a temperature range of 2 to 8 degrees Celsius upon arrival at the destination in Silver Spring, Maryland. This procurement is being handled as a presolicitation notice of intent to sole source, with a response deadline for capability statements set for October 23, 2026.

Defense Health Agency (dha)

POSTED

DEADLINE

Solicitation # SPE2DP-26-R-0001

Solicitation SPE2DP-26-R-0001 is a sole source, firm-fixed price, indefinite delivery, indefinite quantity contract issued by the Defense Logistics Agency for the procurement of Japanese Encephalitis Vaccine (JEV), identified by NSN 6505-01-607-7018. The contract consists of an eighteen-month base term with a guaranteed minimum purchase of 277,760 units and a maximum quantity of 394,240 units. All products must be manufactured in accordance with MPID Number 5 dated 23 July 2024 and delivered FOB Destination to DLA Distribution Susquehanna within 120 days after the date of order. To be eligible for award, offerors must provide proof of FDA approval to manufacture or sell the vaccine or a manufacturer's letter of commitment ensuring supply availability and fixed pricing for the duration of the contract. Proposals must be submitted via DIBBS and include unit pricing, with the government evaluating offers based on price, FDA approval, and adherence to solicitation terms. Strict packaging and marking requirements apply, including compliance with MIL-STD-129 for refrigerated shipments and Medical Marking Standard No. 1. Invoicing and payment will be processed electronically through the Wide Area WorkFlow system.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

VAC to Finished Vaccine ConversionThis subcontract involves the conversion of Government-owned Vaccine Antigen Concentrate into final-use Foot and Mouth Disease vaccine doses for prime contractors supporting USDA APHIS projects. The scope of work includes formulating the concentrate into a usable vaccine, performing filling and packaging within cleanroom facilities, and conducting essential final potency and efficacy testing. The project is managed under the Department of Agriculture and will be performed in Ames, Iowa. To be eligible, the contractor must hold a USDA Veterinary Biological Product License. The solicitation was posted on October 1, 2026, with a response deadline of November 10, 2026, falling under NAICS code 325414.

POSTED

DEADLINE

FMD Vaccine Antigen Concentrate (VAC) ProductionThis subcontract for the Department of Agriculture involves the production of Foot and Mouth Disease Vaccine Antigen Concentrates for prime contractors on USDA APHIS projects. The scope of work includes the purification and concentration of VAC serials, which are produced by engineering Master Seed Viruses or utilizing field strains in accordance with 9 CFR Parts 113 and 114. To qualify, the provider must possess a USDA Veterinary Biological Product License and provide propagation cell line data approved by the Center for Veterinary Biologics. The final deliverables are purified and concentrated FMD VAC serials, with performance taking place in Ames, Iowa. The response deadline for this opportunity is November 10, 2026.

POSTED

DEADLINE

Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC)

Solicitation # 12639527R0001

Solicitation 12639527R0001 is a request for proposals issued by the USDA Animal and Plant Health Inspection Service (APHIS) for an Indefinite Delivery Indefinite Quantity (IDIQ) contract. The requirement covers the purchase, storage, and production of Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC), the conversion of Government-owned VAC into usable finished vaccines, and the direct purchase of finished vaccines. The contract has a ceiling price of 800 million dollars and a long-term performance horizon, featuring five one-year ordering periods starting approximately December 1, 2026, with conversion and delivery of finished vaccines extending through November 30, 2044. The scope of work requires the contractor to produce VAC capable of yielding at least 1.0 million doses and maintain these materials on their premises under strict quality control and temperature standards. Because live FMDV is a Tier 1 Select Agent, the contractor must hold a select agent authorization issued by CDC/APHIS. Finished vaccines must be packaged to maintain temperatures between 2 to 8 degrees Celsius for 24 hours and include electronic temperature monitors. Award will be based on the most advantageous offer considering technical capability, past performance from the last five years, and fair and reasonable pricing. Proposals must be submitted electronically to Stephen Tees by November 10, 2026, at 1700 CT, organized into four separate volumes.

POSTED

DEADLINE

Antithrombin III Procurement

Solicitation # CBP-CON-00260

The National Blood Authority is seeking tenders for the procurement of an Antithrombin III product under solicitation number CBP-CON-00260. While the agency currently maintains supply arrangements for Thrombotrol through the National Fractionation Agreement for Australia, this request for tender opens the process for the provision of these essential medical supplies. Interested parties must submit their responses by the deadline of November 20, 2026. All inquiries and submissions should be directed to the CBP Procurement Team via the provided contact email. Further detailed specifications and requirements are contained within the official request for tender documentation.

National Blood Authority

POSTED

DEADLINE

Proteomics and Protein Expression AnalysisThe Proteomics and Protein Expression Analysis subcontract supports National Institutes of Health projects focused on identifying biomarkers related to substance exposure and brain development. The selected provider will perform protein identification and quantification for prime contractors using a variety of high-sensitivity methods, including mass spectrometry, ELISA, Western blotting, and protein-protein interaction assays via LC-MS/MS. To ensure the integrity of the results, the performing laboratory must adhere to ISO/IEC 17025 quality standards. The primary deliverables for this engagement consist of detailed quantitative biomarker reports and comprehensive protein expression profiles. This effort falls under NAICS code 325414 and is managed through the Department of Health and Human Services.

National Institutes Of Health

POSTED

DEADLINE

Medical Diagnostic Test Kit SupplyThe Defense Logistics Agency under the Department of Defense has issued a subcontract for the supply of 100 E. coli detection test kits. These diagnostic kits must strictly adhere to FDA regulations, specific shelf-life requirements, and Department of Defense medical packaging standards to ensure quality and viability. Classified under NAICS code 325414, this procurement focuses on the delivery of specialized medical diagnostic tools. The contract was posted on August 11, 2026, and is managed through the DLA's acquisition systems to support military medical readiness.

Defense Logistics Agency

POSTED

2 months ago

DEADLINE

N/A

General Info

Agency

N/A

NAICS

325414 - Biological Product (except Diagnostic) Manufacturing

Place of Performance

The Contractor's Facility, GAITHERSBURG, MD, 20879, USA

Set-Aside

NONE

Documents

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseClosed

PostedApr 9

Presolicitation

Response DeadlineMay 1

Deadline has passed

Submission Closed

05/01/2018, 01:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyN/A

Contacts2 people available

OfficeN/A

Organization / Agency

N/A

Office AddressN/A

Contacts

Sherrie N. RandallContracting Officer

contact@example.gov

+1 (555) 000-0000

Christine N GodfreyTeam Lead

contact@example.gov

+1 (555) 000-0000

Full Description

NOTICE OF INTENET TO SOLE SOURCE: The Centers for Disease Control and Prevention (CDC) intends to award a sole source firm-fixed price contract to Emergent Product Development Gaithersburg Inc. The Government intends to purchase 1,617,600 vials of ACAM 2000 Diluent as an ancillary component of the Food And Drug Administration (FDA) licensed ACAM2000 Smallpox Vaccine, by June 30, 2018 with a period of performance of 1 year. Emergent Product Development Gaithersburg Inc. is the only FDA licensed provider of the ACAM 2000 diluent for the ACAM2000 Smallpox Vaccine and therefore is the only source capable to provide this requirement to the Government. Emergent Product Development Gaithersburg Inc.'s manufacturing processes have been validated and are approved by the FDA, (STN 125158, License #1815). The Government intends to negotiate this requirement under the authority of FAR 6.302-1. It is the Government's belief that only one responsible source exists and no other product or services will satisfy agency requirements. This notice of intent is not a request for competitive proposals. A determination to compete this procurement based on a response to this notice is solely within the discretion of the Government. Interested parties who believe they possess the capabilities to satisfy this requirement should submit a capability statement demonstrating their abilities to meet this requirement. All responses must be received by May 1, 2018 at 8AM Eastern Standard Time. All responses must be in writing and can be sent via email to srandall@cdc.gov. No phone calls will be accepted.

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Join 750+ contractors already using CLEATUS